MAP2K7 and prostate carcinoma: Recently, IGHG1 has been reported to facilitate prostate cancer growth via the MEK/ERK/c-Myc pathway, while suppression of IGHG1 expression by siRNA led to growth inhibition and apoptosis induction [27, 28].